• DNDi_Logo_No-Tagline_Full Colour
  • Our work
    • Diseases
      • Sleeping sickness
      • Visceral leishmaniasis
      • Cutaneous leishmaniasis
      • Chagas disease
      • Parasitic worms
      • Mycetoma
      • Dengue
      • Paediatric HIV
      • Cryptococcal meningitis
      • Hepatitis C
      • Pandemic preparedness
      • Antimicrobial resistance
    • Research & development
      • R&D portfolio & list of projects
      • Drug discovery
      • Translational research
      • Clinical trials
      • Registration & access
      • Treatments delivered
    • Advocacy
      • Open and collaborative R&D
      • Transparency of R&D costs
      • Pro-access policies and IP
      • Children’s health
      • Gender equity
      • Climate change
      • AI and new technologies
  • Networks & partners
    • Partnerships
      • Our partners
      • Partnering with us
    • Global networks
      • Chagas Platform
      • Dengue Alliance
      • HAT Platform
      • LEAP Platform
      • redeLEISH Network
    • DNDi worldwide
      • DNDi Switzerland
      • DNDi Eastern Africa
      • DNDi Japan
      • DNDi Latin America
      • DNDi North America
      • DNDi South Asia
      • DNDi South-East Asia
      • DNDi West and Central Africa
  • News & resources
    • News & stories
      • News
      • Stories
      • Statements
      • Viewpoints
      • Social media
      • eNews Newsletter
    • Press
      • Press releases
      • In the media
      • Podcasts, radio & TV
      • Media workshops
    • Resources
      • Scientific articles
      • Our publications
      • Videos
    • Events
  • About us
    • About
      • Who we are
      • Our story
      • How we work
      • Our strategy
      • Our donors
      • Annual reports
      • Our prizes and awards
    • Our people
      • Our leadership
      • Our governance
      • Contact us
    • Work with us
      • Working at DNDi
      • Job opportunities
      • Requests for proposal
  • Donate
  • DNDi_Logo_No-Tagline_Full Colour
  • Our work
    • Diseases
      • Sleeping sickness
      • Visceral leishmaniasis
      • Cutaneous leishmaniasis
      • Chagas disease
      • Parasitic worms
      • Mycetoma
      • Dengue
      • Paediatric HIV
      • Cryptococcal meningitis
      • Hepatitis C
      • Pandemic preparedness
      • Antimicrobial resistance
    • Research & development
      • R&D portfolio & list of projects
      • Drug discovery
      • Translational research
      • Clinical trials
      • Registration & access
      • Treatments delivered
    • Advocacy
      • Open and collaborative R&D
      • Transparency of R&D costs
      • Pro-access policies and IP
      • Children’s health
      • Gender equity
      • Climate change
      • AI and new technologies
  • Networks & partners
    • Partnerships
      • Our partners
      • Partnering with us
    • Global networks
      • Chagas Platform
      • Dengue Alliance
      • HAT Platform
      • LEAP Platform
      • redeLEISH Network
    • DNDi worldwide
      • DNDi Switzerland
      • DNDi Eastern Africa
      • DNDi Japan
      • DNDi Latin America
      • DNDi North America
      • DNDi South Asia
      • DNDi South-East Asia
      • DNDi West and Central Africa
  • News & resources
    • News & stories
      • News
      • Stories
      • Statements
      • Viewpoints
      • Social media
      • eNews Newsletter
    • Press
      • Press releases
      • In the media
      • Podcasts, radio & TV
      • Media workshops
    • Resources
      • Scientific articles
      • Our publications
      • Videos
    • Events
  • About us
    • About
      • Who we are
      • Our story
      • How we work
      • Our strategy
      • Our donors
      • Annual reports
      • Our prizes and awards
    • Our people
      • Our leadership
      • Our governance
      • Contact us
    • Work with us
      • Working at DNDi
      • Job opportunities
      • Requests for proposal
  • Donate
Home > Stories

Nancy Chemluo, A Mother’s Struggle to Cure a Child with Kala Azar

Nancy Cheluo had two sons affected by Kala Azar. East Pokot, Kenya.

Home > Stories

Nancy Chemluo, A Mother’s Struggle to Cure a Child with Kala Azar

Nancy Cheluo had two sons affected by Kala Azar. East Pokot, Kenya.

Nancy Cheluo had two sons affected by Kala Azar. East Pokot, Kenya.
8 May 2013

West Pokot Kenya

Thursday, 23 August 2012, a sunny and very hot afternoon in West Pokot, Kenya: Dust devils circle into the air as pickup trucks packed with passengers drop off numbers of people, who all settle under a large tree in the village. This is where the community gathers for elders’ meetings. It is here that Nancy Chemluo recounts how kala azar affected two of her sons, and how she and her community changed their approach to seeking treatment.

‘A year ago, my five-year-old son was unwell. He had fever, headache, and nose bleeds. After some investigation, we found out his symptoms were those of kala azar. We tried to treat him using home remedies, which my community is accustomed to using when someone falls ill. So if one of my neighbours or anyone I know was going to Kerio valley, I would give them the money to buy me the traditional medicine. I spent a lot of money on transport and these traditional remedies.

So many people have suffered and still suffer from kala azar in my community. We have so many anthills here, and that is where the insect that spreads kala azar lives. My message to my community and anyone who will hear me is this: traditional forms of medicine for kala azar do not work! My son took them and showed no signs of improvement. He only got worse. It was like a death sentence.
I was so desperate for a solution for him. I then had a chance meeting with one of my neighbours, who told me I could get treatment in Kimalel and gave me the mobile number of a staff member. That phone call saved my son’s life.

Since then, we as a community have come to know KEMRI and DNDi. So when my four-year-old son, Jamesta Limareng, got sick last month, my family gathered at my house and made arrangements to have him taken right away to the treatment centre in Kimalel. His recovery was much faster than that of my older son: instead of a 30-day treatment, Jamesta was treated using the 17-day treatment [SSG&PM]. The shorter and better the treatment, the better for us all.’

Visceral leishmaniasis Kenya

Read, watch, share

Loading...
Acoziborole pill in hand
Press releases
27 Feb 2026

Acoziborole Winthrop, developed by DNDi and Sanofi, receives European Medicines Agency positive opinion as three-tablet, single-dose treatment for most common form of sleeping sickness

Lab activities
News
20 Feb 2026

DNDi welcomes GHIT support for lead identification of a novel chemical series in the Eisai-led Chagas disease project

Press releases
10 Feb 2026

DNDi and Dubai Health launch Middle East partnership to advance research and training in neglected diseases

Statements
10 Feb 2026

Statement on Brazil’s draft National Action Plan for Antimicrobial Resistance

Statements
3 Feb 2026

DNDi interventions at the 158th Session of the WHO Executive Board

Sir Nicholas White
News
2 Feb 2026

Message on the passing of Professor Sir Nicholas White from DNDi Board Chair Dr Marie-Paule Kieny and DNDi Executive Director Dr Luis Pizarro

News
30 Jan 2026

Imperial and DNDi strengthen partnership to accelerate treatments for neglected diseases 

News
30 Jan 2026

Science can end the neglect: but only if we act together – World NTD Day 2026

VIEW ALL

Help neglected patients

To date, we have delivered fourteen new treatments, saving millions of lives.

Our goal is to deliver 25 new treatments in our first 25 years. You can help us get there. 

GIVE NOW
Linkedin-in Instagram Twitter Facebook-f Youtube
International non-profit developing safe, effective, and affordable treatments for the most neglected patients.

Learn more

  • Diseases
  • Neglected tropical diseases
  • R&D portfolio
  • Policy advocacy

Get in touch

  • Our offices
  • Contact us
  • Integrity Line

Support us

  • Donate
  • Subscribe to eNews

Work with us

  • Join research networks
  • Jobs
  • RFPs
  • Terms of Use   
  •   Acceptable Use Policy   
  •   Privacy Policy   
  •   Cookie Policy   
  •   Our policies   

  • Except for images, films, and trademarks which are subject to DNDi’s Terms of Use, content on this site is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International license